Filtered By:
Drug: Rituxan
This page shows you your search results in order of relevance. This is page number 15.
Order by Relevance | Date
Total 7090 results found since Jan 2013.
Development of anti-rituximab antibodies in rituximab-treated patients: Related parameters & amp; consequences
Indian J Med Res. 2022 Mar&Apr;155(3&4):335-346. doi: 10.4103/ijmr.IJMR_312_19.ABSTRACTThe utilization of the monoclonal antibodies (mAbs) as therapeutic agents is one of the most favourable fields in immunotherapy. The immunogenicity of mAbs is one of the major parameters that may restrict their therapeutic and diagnostic applications. Rituximab, a chimeric mAb against CD20, is attached to the B-cell membrane-linked CD20 and is used to treat some B-cell-related malignancies, a number of autoantibody-mediated autoimmune disorders and improvement of graft survival. The risk of anti-rituximab antibody (ARA) development and A...
Source: The Indian Journal of Medical Research - September 20, 2022 Category: Biomedical Science Authors: Fatemeh Saffari Abdollah Jafarzadeh Source Type: research
Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type on the Dorsal Foot in a Senior Woman: A Case Report
J Am Podiatr Med Assoc. 2022 Nov-Dec;112(6):21-143. doi: 10.7547/21-143.ABSTRACTPrimary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL-LT) is a rare variant of the cutaneous B-cell lymphomas, with rapid growth and poor prognosis. Here, we report a case of PCDLBCL-LT on the foot in a senior woman. An 81-year-old woman presented with a rapidly growing mass on her left foot, and discoloration in both lower legs over the past 2 months was analyzed. Physical examination revealed hyperpigmented macules and papules on both lower extremities and a 3.0 × 2.0 × 0.5-cm, gray-dark nodule on the dorsal surface of the left...
Source: Journal of the American Podiatric Medical Association - December 16, 2022 Category: Podiatry Authors: Joel Kelly Gene Mirkin Joon Yim Xingpei Hao Source Type: research
